Drug maker tracks Long-Term safety of new myeloma therapy
NCT ID NCT06479954
Summary
This study is monitoring the long-term safety and effectiveness of the drug elranatamab in patients with relapsed and refractory multiple myeloma, a hard-to-treat blood cancer. It aims to collect real-world information on side effects, especially serious ones like cytokine release syndrome, and how well the drug works over time. The study is for patients in Japan who have already received at least one dose of the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.